Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on inflammation and cardiovascular disease

Professor J. Deanfield (London, GB)

Presentation thumbnail

Associations between C-reactive protein levels and mortality in individuals with atherosclerotic cardiovascular disease and chronic kidney disease: results from the UK Discover database

Professor K. Ray (London, GB)

Abstract Slides Video

Presentation thumbnail

Cumulative adiposity burden and cardiovascular risk trajectories: validating the 2025 clinical obesity criteria

Doctor J. Yang (Shanghai, CN)

Abstract Slides Video

Presentation thumbnail

Sex differences in cardio-kidney metabolic syndrome: insights from the FINE-HEART pooled analysis of >18,000 trial participants

Doctor M. Pabon (Boston, US)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiorenal-metabolic triad: the global health challenge

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

Congress Presentation

Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in diabetic patients with a higher impact on women

Congress Presentation

Case 2: gender differences in cardiovascular risk, treatment, and outcomes

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources